Decoy Therapeutics (NASDAQ:DCOY) Shares Shorted: Short Interest Down 35.1% in October

Posted by James Conley on Nov 4th, 2026

Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totaling 97,605 shares, a decline of 35.1% from the September 30th total of 150,336 shares. Based on an average daily trading volume, of 119,437 shares, the short-interest ratio is currently 0.8 days. Approximately 4.2% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Decoy Therapeutics in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $30.00.

Read Our Latest Analysis on DCOY

Decoy Therapeutics Stock Performance

Decoy Therapeutics stock opened at $1.11 on Wednesday. The company’s 50-day moving average price is $2.08 and its 200-day moving average price is $5.35. Decoy Therapeutics has a twelve month low of $0.90 and a twelve month high of $43.92.

Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($4.46) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter. As a group, equities analysts forecast that Decoy Therapeutics will post -8.96 EPS for the current year.

About Decoy Therapeutics

(Get Free Report)

Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms.

The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.

Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited.